Minocycline for the Treatment of Early-Phase Schizophrenia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00733057 |
Recruitment Status
:
Completed
First Posted
: August 12, 2008
Last Update Posted
: August 12, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Negative and Cognitive Symptoms in Schizophrenia | Drug: Minocycline Drug: Placebo (200 mg/day) | Phase 3 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 70 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Prevention |
Official Title: | A Double Blind Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia |
Study Start Date : | August 2003 |
Actual Primary Completion Date : | March 2007 |
Actual Study Completion Date : | March 2007 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
Minocycline treatment
|
Drug: Minocycline
Minocycline as an add-on drug (200 mg/day)
|
Placebo Comparator: 2
Placebo
|
Drug: Placebo (200 mg/day) |
- Scale for Assessment of Negative Symptoms (SANS) [ Time Frame: Change in SANS scores over the 6-month study ]
- PANSS, CGI, CDS, ITAQ, CANTAB measures, adverse events. [ Time Frame: Change during the 6-month duration of the study ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age between 18-35 years;
- current DSM-IV diagnosis of schizophrenia confirmed by the Structured Clinical Interview for DSM-IV (SCID) conducted by a trained psychiatrist.
- being at an early phase of the disorder (i.e., within five years of their first exposure to neuroleptic treatment;18)
- did not receive antipsychotic treatment for six months preceding current symptom exacerbation;
- baseline total score of more than 60 on the Positive and Negative Syndrome Scale (PANSS).
- Initiation of treatment with atypical antipsychotic medication equal or less than 14 days prior to study entry (risperidone, olanzapine, quetiapine, or clozapine; 200-600 mg/day chlorpromazine equivalent doses);
- able to comprehend the procedure and aims of the study.
Exclusion Criteria:
- acute, unstable, significant or untreated medical illness beside schizophrenia;
- pregnant or breast-feeding females;
- A DSM-IV diagnosis of substance abuse or dependency;
- Known contraindication to minocycline treatment.
- Treatment with minocycline or Beta-lactam antibiotics in the preceding half year before study entry.
- Under compulsory hospitalization.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00733057
Israel | |
The Emotion-Cognition Research Center, The Shalvata Mental Health Care Center, P.O.B. 94. | |
Hod-Hasharon, Israel, 70300 |
Principal Investigator: | Yechiel - Levkovitz, M.D. PhD. | Shalvata Mental Health Center |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Dr. Yechiel Levkovitz, M.D., Shalvata Mental Health Center |
ClinicalTrials.gov Identifier: | NCT00733057 History of Changes |
Other Study ID Numbers: |
SMRI-GRANT-02T-244 |
First Posted: | August 12, 2008 Key Record Dates |
Last Update Posted: | August 12, 2008 |
Last Verified: | August 2008 |
Keywords provided by Shalvata Mental Health Center:
Minocycline Schizophrenia Negative symptoms Cognitive |
Additional relevant MeSH terms:
Schizophrenia Neurobehavioral Manifestations Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Neurologic Manifestations |
Nervous System Diseases Signs and Symptoms Minocycline Anti-Bacterial Agents Anti-Infective Agents |